Table 1.
Patient demographic, tumor, and treatment details (n = 111).
| Variable | No. (%) or Median (IQR) |
|---|---|
| Age at surgery, years | 62 (53–69) |
| Sex | |
| Female | 65 (59) |
| Male | 46 (41) |
| Smoking status | |
| Never | 21 (19) |
| Ever | 90 (81) |
| Pack-years | 30 (4.5–48) |
| Radiologic primary tumor size, cm (n = 102) | 3.3 (2.0–4.6) |
| Primary tumor SUVmax (n = 87) | 9.6 (6.3–15) |
| FEV1, % (n = 103) | 91 (79–101) |
| DLCO, % (n = 103) | 82 (67–94) |
| Extrathoracic metastatic site at diagnosis | |
| Adrenal | 6 (5) |
| Bone | 21 (19) |
| Brain | 57 (51) |
| Liver | 8 (7) |
| Other a | 9 (8) |
| Multiple | 10 (9) |
| Total metastatic sites | |
| 1 | 101 (91) |
| 2 | 8 (7) |
| 3 | 2 (2) |
| Total metastatic lesions | |
| 1 | 87 (78) |
| 2 | 15 (14) |
| 3 | 7 (6) |
| 4 | 1 (1) |
| 5 | 1 (1) |
| Local consolidative therapy for metastasis | |
| No | 18 (16) |
| Yes | 93 (84) |
| Neoadjuvant therapy | |
| None | 23 (21) |
| Systemic therapy only b | 77 (69) |
| Chemoradiotherapy | 11 (10) |
| Operative approach to primary tumor | |
| Open | 70 (63) |
| VATS | 41 (37) |
| Primary tumor resection type | |
| Lobectomy | 85 (77) |
| Segmentectomy | 26 (23) |
| Histologic subtype | |
| Lepidic | 0 (0) |
| Acinar/papillary | 30 (27) |
| Micropapillary/solid | 14 (13) |
| Unknown | 67 (60) |
| Final pathologic diagnosis | |
| Adenocarcinoma | 80 (72) |
| Squamous cell carcinoma | 6 (5) |
| Other | 14 (13) |
| No viable tumor | 11 (10) |
| Lymphovascular invasion | |
| No | 45 (41) |
| Yes | 60 (54) |
| Unknown | 6 (5) |
| Visceral pleural invasion | |
| No | 62 (56) |
| Yes | 45 (41) |
| Unknown | 4 (4) |
| Pathologic primary tumor size, cm | 2.5 (1.6–3.6) |
| Pathologic stage (AJCC 8th edition) c | |
| I | 5 (5) |
| II | 2 (2) |
| III | 2 (2) |
| IV | 102 (92) |
| Adjuvant therapy | |
| None | 67 (60) |
| Systemic therapy only b | 31 (28) |
| Radiotherapy only | 8 (7) |
| Chemoradiotherapy | 5 (5) |
AJCC, American Joint Committee on Cancer; DLCO, diffusion capacity of the lungs for carbon monoxide; FEV1, forced expiratory volume in 1 s; SUVmax, maximum standardized uptake value; VATS, video assisted thoracoscopic surgery. a Includes eye, intestine, omentum, pancreas, scalp, spleen, and perianal soft tissue. b Includes chemotherapy, immunotherapy, and targeted therapy. c Pathologic stage determined at the time of primary tumor resection; staging reflects prior treatment to metastatic sites.